MA27427A1 - Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie - Google Patents

Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie

Info

Publication number
MA27427A1
MA27427A1 MA28130A MA28130A MA27427A1 MA 27427 A1 MA27427 A1 MA 27427A1 MA 28130 A MA28130 A MA 28130A MA 28130 A MA28130 A MA 28130A MA 27427 A1 MA27427 A1 MA 27427A1
Authority
MA
Morocco
Prior art keywords
benzimidazole
cancer therapy
thiophene compounds
compounds
thiophene
Prior art date
Application number
MA28130A
Other languages
English (en)
Inventor
Iii Clarence W Andrews
Mui Cheung
Ronda G Davis-Ward
David Harold Drewry
Kyle Allen Emmitte
Robert Dale Hubbard
Kevin W Kuntz
James Andrew Linn
Robert Anthony Mook
Gary Keith Smith
James Marvin Veal
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA27427A1 publication Critical patent/MA27427A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés représentés pas la formule (I), des compositions pharmaceutiques qui renferment ces composés, des procédés de préparation de ces composés ainsi que leur utilisation comme agents pharmaceutiques
MA28130A 2002-08-08 2005-03-04 Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie MA27427A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40200802P 2002-08-08 2002-08-08

Publications (1)

Publication Number Publication Date
MA27427A1 true MA27427A1 (fr) 2005-07-01

Family

ID=31715769

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28130A MA27427A1 (fr) 2002-08-08 2005-03-04 Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie

Country Status (18)

Country Link
US (2) US20060074119A1 (fr)
EP (1) EP1546137A1 (fr)
JP (1) JP2006505522A (fr)
KR (1) KR20050071471A (fr)
CN (1) CN1688576A (fr)
AU (1) AU2003265348B2 (fr)
BR (1) BR0313160A (fr)
CA (1) CA2493908A1 (fr)
IL (1) IL166328A0 (fr)
IS (1) IS7657A (fr)
MA (1) MA27427A1 (fr)
MX (1) MXPA05001544A (fr)
NO (1) NO20050525L (fr)
NZ (1) NZ538134A (fr)
PL (1) PL375532A1 (fr)
RU (1) RU2296758C2 (fr)
WO (1) WO2004014899A1 (fr)
ZA (1) ZA200500864B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2005021531A1 (fr) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs d'un ensemble de benzimidazolyle c n substitue
WO2005037827A1 (fr) * 2003-10-16 2005-04-28 Smithkline Beecham Corporation Procede de preparation de thiophenes de benzimidazole
US20070167499A1 (en) * 2003-10-27 2007-07-19 A*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications
DE602004012891T2 (de) 2003-12-18 2009-04-09 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
JP2007519720A (ja) * 2004-01-28 2007-07-19 スミスクライン ビーチャム コーポレーション チアゾール化合物
GB0402809D0 (en) * 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (fr) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
EP1632493A1 (fr) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dérivés de dihydropteridine, méthodes de préparation et utilisation en tant que médicament
CA2577947A1 (fr) 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. Nouveaux derives d'imidazoles substitues
AU2005301568B2 (en) 2004-11-08 2011-06-09 Msd K.K. Novel fused imidazole derivative
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JP4932735B2 (ja) 2004-12-17 2012-05-16 アムジエン・インコーポレーテツド アミノピリミジン化合物および使用方法
AR055616A1 (es) 2005-09-06 2007-08-29 Smithkline Beecham Corp Compuestos de tiofeno bencimidazol
WO2007030359A1 (fr) * 2005-09-06 2007-03-15 Smithkline Beecham Corporation Composés de thiophène de benzimidazole comme modulateurs plk
MX2008003172A (es) * 2005-09-06 2008-03-18 Smithkline Beecham Corp Proceso regioselectivo para la preparacion de bencimidazol-tiofenos.
UA92180C2 (en) * 2005-09-06 2010-10-11 Смиткляйн Бичам Корпорейшн Benzimidazole thiophene compounds as plk inhibitors
CA2637335A1 (fr) * 2006-01-23 2007-08-02 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides utiles en tant qu'inhibiteurs de proteines kinases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
US7829590B2 (en) 2006-04-13 2010-11-09 Guy Brenchley Thiophene-carboxamides useful as inhibitors of protein kinases
AU2007267986A1 (en) * 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007139795A1 (fr) * 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophène-carboxamides inhibiteurs des protéines kinases
WO2007143506A2 (fr) * 2006-06-02 2007-12-13 Smithkline Beecham Corporation Composés d'éther benzylique de benzimidazole thiophène substitué non cyclique
US7615643B2 (en) 2006-06-02 2009-11-10 Smithkline Beecham Corporation Benzimidazole thiophene compounds
JP2009539770A (ja) * 2006-06-02 2009-11-19 スミスクライン ビーチャム コーポレーション Ｐｌｋに対する活性を有するベンゾイミダゾール置換チオフェン誘導体
DK2044084T3 (en) 2006-07-13 2016-05-09 Janssen Pharmaceutica Nv MTKI-quinazoline derivatives
WO2008021337A1 (fr) 2006-08-15 2008-02-21 Wyeth Dérivés oxazinan-2-one utiles comme modulateurs pr
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
WO2008021309A1 (fr) 2006-08-15 2008-02-21 Wyeth Dérivés d'imidazolidin-2-one utiles en tant que modulateurs pr
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
WO2008070354A2 (fr) * 2006-10-31 2008-06-12 Smithkline Beecham Corporation Benzidimidazole thiophènes substitués en 5 et 6 pour plk
WO2008153701A1 (fr) * 2007-05-24 2008-12-18 Schering Corporation Composés d'inhibition de l'activité de ksp kinésine
WO2009002916A2 (fr) * 2007-06-26 2008-12-31 Smithkline Beecham Corporation Procédés de préparation de thiophènes de benzimidazole
WO2009003911A1 (fr) * 2007-06-29 2009-01-08 4Sc Ag Thiophène-imidazopyridines
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
EP3098223A1 (fr) 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Forme cristalline d'un dérivé de dihydroptéridione
BRPI0817897A2 (pt) * 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
EP2100894A1 (fr) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase)
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010012745A2 (fr) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
EP2379543A2 (fr) * 2008-12-18 2011-10-26 F. Hoffmann-La Roche AG Thiazolyl-benzimidazoles
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CA2750565C (fr) * 2009-01-30 2015-10-20 Glaxosmithkline Llc Chlorhydrate de n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide cristallin
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
US20120329803A1 (en) 2010-02-17 2012-12-27 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
WO2012021611A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
EP2603216A4 (fr) 2010-08-11 2013-12-18 Millennium Pharm Inc Hétéroaryles et utilisations
MA34797B1 (fr) 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
WO2012051410A2 (fr) 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
DK3738434T3 (da) 2011-12-28 2023-12-04 Global Blood Therapeutics Inc Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering
WO2013102145A1 (fr) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Composés d'aldéhydes hétéroaryles substitués et leurs procédés d'utilisation dans l'accroissement de l'oxygénation tissulaire
US9018380B2 (en) 2012-08-24 2015-04-28 Boar of Regents, The University of Texas System Heterocyclic modulators of HIF activity for treatment of disease
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
KR102280614B1 (ko) * 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
WO2015011236A1 (fr) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Traitement du syndrome myélodysplasique
CN103408540B (zh) * 2013-08-22 2016-05-18 中国药科大学 2-唑环取代噻吩类plk1抑制剂及其用途及其用途
CN105683182A (zh) 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SI3102208T2 (sl) 2014-02-07 2024-10-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
EP3932914A1 (fr) 2015-03-13 2022-01-05 Valo Health, Inc. Composés alpha-cinnamidiques et compositions comme inhibiteurs de hdac8
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3860975B1 (fr) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose
JP7509772B2 (ja) 2018-11-19 2024-07-02 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンのモジュレーター
CN119707936B (zh) * 2025-02-25 2025-07-25 中南大学 一种2,4-二取代-5-氟嘧啶衍生物的盐的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859648A (en) * 1984-12-28 1989-08-22 Mobil Oil Corporation Layered metal chalcogenides containing interspathic polymeric chalcogenides
FR2600000B1 (fr) * 1986-06-13 1989-04-14 Extramet Sa Procede et dispositif de granulation d'un metal fondu
US4818270A (en) * 1986-08-28 1989-04-04 Monsanto Company 2-(Heteroamino)-4,5-substituted-oxazole/thiazole compounds as herbicide antidotes, compositions and use
US4859684A (en) * 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
US5151424A (en) * 1987-07-01 1992-09-29 Janssen Pharmaceutica N.V. Pharmacologically active (Bicyclic heterocyclyl)methyl and -hetero) substituted hexahydro-1H-azepines and pyrrolidines
US5342957A (en) * 1988-11-29 1994-08-30 Janssen Pharmaceutica N.V. Benzimidazoles useful in treating epithelial disorders
US5643934A (en) * 1991-03-28 1997-07-01 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz [CD]indoles
US5457102A (en) * 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
DE4329177A1 (de) * 1993-08-30 1995-03-02 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Serin-Threonin-Kinasen
US5955613A (en) * 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
AU738304B2 (en) * 1995-10-13 2001-09-13 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
AU7715198A (en) * 1997-06-04 1998-12-21 Eli Lilly And Company Anti-viral compounds
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6465484B1 (en) * 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
JP3256513B2 (ja) * 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US6358738B1 (en) * 1998-05-13 2002-03-19 The President And Fellows Of Harvard College Polo box therapeutic compositions, methods, and uses therefor
CA2337828C (fr) * 1998-07-16 2010-08-17 Aventis Pharma Deutschland Gmbh Derives d'acide phosphinique et d'acide phosphonique utilises comme medicaments
EP1109555A4 (fr) * 1998-08-31 2001-11-21 Merck & Co Inc Nouveaux inhibiteurs d'angiogenese
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
US6642425B2 (en) * 2002-03-05 2003-11-04 Sasol North America Inc. Reactive distillation process for the alkylation of aromatic hydrocarbons
US20040002524A1 (en) * 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists

Also Published As

Publication number Publication date
WO2004014899A1 (fr) 2004-02-19
US20060074119A1 (en) 2006-04-06
KR20050071471A (ko) 2005-07-07
JP2006505522A (ja) 2006-02-16
AU2003265348A1 (en) 2004-02-25
IL166328A0 (en) 2006-01-15
NZ538134A (en) 2006-03-31
ZA200500864B (en) 2006-04-26
NO20050525L (no) 2005-05-06
CN1688576A (zh) 2005-10-26
PL375532A1 (en) 2005-11-28
BR0313160A (pt) 2005-07-12
CA2493908A1 (fr) 2004-02-19
EP1546137A1 (fr) 2005-06-29
AU2003265348B2 (en) 2007-08-16
RU2296758C2 (ru) 2007-04-10
MXPA05001544A (es) 2005-04-19
US20080269298A1 (en) 2008-10-30
RU2005102390A (ru) 2006-01-10
IS7657A (is) 2005-01-20

Similar Documents

Publication Publication Date Title
MA29213B1 (fr) Quinolones a substitution macrolones - amino
EP2289891A3 (fr) Nouveaux dérivés de polyquinoléines et leur utilisation thérapeutique.
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
BR0206955A (pt) Ligantes de receptores de canabinóides
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA31683B1 (fr) Composes et procedes pour moduler fxr
YU56995A (sh) Soli derivata indola
CA2348725A1 (fr) Analogues de la vitamine d
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
BR0112030A (pt) Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor
MA29909B1 (fr) Derives de pyridazine
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
EP1819227A4 (fr) Formulation pharmaceutique de decitabine
BR9808953A (pt) Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica
BR9811818A (pt) Uso de um composto, composto, e, composição farmacêutica
BR0312729A (pt) Novos derivados de indol-3-enxofre